CN105682656B - 调节法尼醇x受体的组合物和方法 - Google Patents

调节法尼醇x受体的组合物和方法 Download PDF

Info

Publication number
CN105682656B
CN105682656B CN201480058975.8A CN201480058975A CN105682656B CN 105682656 B CN105682656 B CN 105682656B CN 201480058975 A CN201480058975 A CN 201480058975A CN 105682656 B CN105682656 B CN 105682656B
Authority
CN
China
Prior art keywords
methyl
pyrazole
dihydrobenzopyrans
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480058975.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105682656A (zh
Inventor
D·基亚内利
刘晓东
V·莫尔泰尼
J·内尔森
J·罗兰
P·鲁克尔
D·图利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105682656(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN105682656A publication Critical patent/CN105682656A/zh
Application granted granted Critical
Publication of CN105682656B publication Critical patent/CN105682656B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201480058975.8A 2013-11-05 2014-11-04 调节法尼醇x受体的组合物和方法 Expired - Fee Related CN105682656B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05
US61/900,013 2013-11-05
PCT/US2014/063948 WO2015069666A1 (en) 2013-11-05 2014-11-04 Compositions and methods for modulating farnesoid x receptors

Publications (2)

Publication Number Publication Date
CN105682656A CN105682656A (zh) 2016-06-15
CN105682656B true CN105682656B (zh) 2019-11-05

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480058975.8A Expired - Fee Related CN105682656B (zh) 2013-11-05 2014-11-04 调节法尼醇x受体的组合物和方法

Country Status (42)

Country Link
US (5) US9682939B2 (enExample)
EP (1) EP3065738B1 (enExample)
JP (1) JP6424231B2 (enExample)
KR (1) KR102350357B1 (enExample)
CN (1) CN105682656B (enExample)
AP (1) AP2016009165A0 (enExample)
AR (1) AR098316A1 (enExample)
AU (1) AU2014346919B2 (enExample)
BR (1) BR112016009630B1 (enExample)
CA (1) CA2927705C (enExample)
CL (1) CL2016000982A1 (enExample)
CR (1) CR20160212A (enExample)
CU (1) CU24375B1 (enExample)
CY (1) CY1120273T1 (enExample)
DK (1) DK3065738T3 (enExample)
EA (1) EA030430B1 (enExample)
ES (1) ES2670984T3 (enExample)
GT (1) GT201600085A (enExample)
HR (1) HRP20180817T1 (enExample)
HU (1) HUE039155T2 (enExample)
IL (1) IL245242B (enExample)
JO (1) JO3454B1 (enExample)
LT (1) LT3065738T (enExample)
MA (1) MA39088B1 (enExample)
MX (1) MX364834B (enExample)
MY (1) MY175903A (enExample)
NO (1) NO3105103T3 (enExample)
NZ (1) NZ719078A (enExample)
PE (1) PE20160682A1 (enExample)
PH (1) PH12016500777A1 (enExample)
PL (1) PL3065738T3 (enExample)
PT (1) PT3065738T (enExample)
RS (1) RS57179B1 (enExample)
SG (1) SG11201603026PA (enExample)
SI (1) SI3065738T1 (enExample)
SV (1) SV2016005192A (enExample)
TN (1) TN2016000143A1 (enExample)
TR (1) TR201807321T4 (enExample)
TW (1) TWI662027B (enExample)
UY (1) UY35818A (enExample)
WO (1) WO2015069666A1 (enExample)
ZA (1) ZA201602555B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CU24375B1 (es) 2013-11-05 2018-12-05 Novartis Ag Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
WO2016174616A1 (en) * 2015-04-30 2016-11-03 Novartis Ag Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors
AU2017223155B2 (en) 2016-02-22 2019-08-22 Novartis Ag Methods for using FXR agonists
PL3730487T3 (pl) 2016-06-13 2022-08-16 Gilead Sciences, Inc. Pochodne azetydyny jako modulatory fxr (nr1h4)
CA3252823A1 (en) 2016-06-13 2025-02-25 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6915050B2 (ja) * 2016-09-14 2021-08-04 ノバルティス アーゲー Ｆｘｒアゴニストの新規のレジーム
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
MX2019003889A (es) * 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
EP4122464B1 (en) 2017-03-28 2024-05-15 Gilead Sciences, Inc. Therapeutic combinations for treating liver diseases
EP3634966B1 (en) * 2017-06-05 2024-06-05 National University of Singapore Compounds useful in inhibiting human trefoil factor 3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MA49903A (fr) 2017-08-15 2020-06-24 Inflazome Ltd Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
CN111093705A (zh) * 2017-09-13 2020-05-01 诺华股份有限公司 包含fxr激动剂的组合
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
MA50567A (fr) 2017-11-09 2020-09-16 Inflazome Ltd Nouveaux composés de sulfonamide carboxamide
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
JP7555327B2 (ja) 2018-07-25 2024-09-24 ノバルティス アーゲー Ｎｌｒｐ３インフラマソーム阻害剤
PE20211907A1 (es) 2019-01-15 2021-09-28 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
CA3233305A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
CN117202905A (zh) 2021-01-14 2023-12-08 埃尼奥制药公司 Fxr激动剂和ifn用于治疗hbv感染的协同效果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4577206A2 (en) * 2022-08-26 2025-07-02 Celmatix Inc. Novel modulators of fshr and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448791A (zh) * 2006-05-24 2009-06-03 伊莱利利公司 Fxr激动剂
CN101743232A (zh) * 2007-07-16 2010-06-16 伊莱利利公司 调节fxr的化合物和方法
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
US7486960B2 (en) * 2006-09-15 2009-02-03 Thales Avionics, Inc. System and method for wirelessly transferring content to and from an aircraft
CU24375B1 (es) 2013-11-05 2018-12-05 Novartis Ag Derivados de pirazol fusionados activos como moduladores del receptor de farnesoide x
WO2016174616A1 (en) 2015-04-30 2016-11-03 Novartis Ag Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448791A (zh) * 2006-05-24 2009-06-03 伊莱利利公司 Fxr激动剂
CN101743232A (zh) * 2007-07-16 2010-06-16 伊莱利利公司 调节fxr的化合物和方法
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr

Also Published As

Publication number Publication date
EA030430B1 (ru) 2018-08-31
EA201690930A1 (ru) 2016-08-31
US9682939B2 (en) 2017-06-20
CN105682656A (zh) 2016-06-15
TR201807321T4 (tr) 2018-06-21
NO3105103T3 (enExample) 2018-05-12
US20170275256A1 (en) 2017-09-28
AR098316A1 (es) 2016-05-26
CU24375B1 (es) 2018-12-05
AU2014346919A1 (en) 2016-05-12
IL245242B (en) 2019-03-31
ES2670984T3 (es) 2018-06-04
MX2016005865A (es) 2016-07-13
TWI662027B (zh) 2019-06-11
US10683271B2 (en) 2020-06-16
IL245242A0 (en) 2016-06-30
KR20160079091A (ko) 2016-07-05
CU20160063A7 (es) 2016-09-30
JP2016535784A (ja) 2016-11-17
US20190062283A1 (en) 2019-02-28
KR102350357B1 (ko) 2022-01-14
EP3065738A1 (en) 2016-09-14
BR112016009630B1 (pt) 2021-02-09
SI3065738T1 (en) 2018-06-29
LT3065738T (lt) 2018-05-10
CA2927705C (en) 2021-09-21
PE20160682A1 (es) 2016-07-23
PL3065738T3 (pl) 2018-07-31
MA39088B1 (fr) 2018-06-29
ZA201602555B (en) 2017-06-28
GT201600085A (es) 2019-07-19
TN2016000143A1 (en) 2017-10-06
JO3454B1 (ar) 2020-07-05
CY1120273T1 (el) 2019-07-10
UY35818A (es) 2015-05-29
JP6424231B2 (ja) 2018-11-14
PH12016500777B1 (en) 2016-05-30
US11021446B2 (en) 2021-06-01
DK3065738T3 (en) 2018-06-06
MA39088A1 (fr) 2017-07-31
US20160340317A1 (en) 2016-11-24
AU2014346919B2 (en) 2017-02-02
US20210253534A1 (en) 2021-08-19
WO2015069666A1 (en) 2015-05-14
TW201612163A (en) 2016-04-01
US10077240B2 (en) 2018-09-18
BR112016009630A8 (pt) 2020-04-07
PT3065738T (pt) 2018-06-04
CR20160212A (es) 2016-07-22
US20200247757A1 (en) 2020-08-06
HUE039155T2 (hu) 2018-12-28
SG11201603026PA (en) 2016-05-30
EP3065738B1 (en) 2018-02-28
HRP20180817T1 (hr) 2018-06-29
CL2016000982A1 (es) 2016-10-07
CA2927705A1 (en) 2015-05-14
MX364834B (es) 2019-05-08
RS57179B1 (sr) 2018-07-31
PH12016500777A1 (en) 2016-05-30
AP2016009165A0 (en) 2016-04-30
NZ719078A (en) 2018-07-27
MY175903A (en) 2020-07-15
SV2016005192A (es) 2016-11-21

Similar Documents

Publication Publication Date Title
CN105682656B (zh) 调节法尼醇x受体的组合物和方法
JP2014500319A (ja) ファルネソイドｘ受容体を調節するための組成物および方法
JP2014500318A (ja) ファルネソイドｘ受容体を調節するための組成物および方法
CN114008040B (zh) 用于调节fxr的化合物
JP6691552B2 (ja) ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
JP7449300B2 (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
HK1224565B (en) Compositions and methods for modulating farnesoid x receptors
HK1224565A1 (en) Compositions and methods for modulating farnesoid x receptors
NZ795495A (en) Aminothiazole compounds as c-Kit inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191105